Phlox Therapeutics raises €1.9M to advance RNA therapies for rare heart diseases
December 11, 2024Phlox Therapeutics, a biotechnology spin-off from Amsterdam UMC, has secured €1.9 million in seed funding to accelerate the development of RNA-based therapies for rare genetic heart conditions. This funding brings Phlox closer to delivering life-changing treatments for patients with genetic laminopathies, a critical unmet need in cardiovascular health.
This round of funding adds ROM Utrecht Region to the existing syndicate of FIRST fund, Amsterdam UMC Venture Holding, and Utrecht Health Seed Fund (USHF). With their backing, Phlox is set to advance its lead program through preclinical development. Supported by IXA and AMC Ventures Holding, prof. dr. Pinto founded the company in 2022, together with prof. dr. Eva van Rooij and with Margien Boels, PhD as its initiating business director.
The investment marks an important milestone for Phlox Therapeutics, as it continues to pioneer new RNA-based approaches to treat rare cardiovascular conditions. Phlox: “With this funding, we are energized to make substantial strides toward developing new treatment options that could transform the lives of those affected by cardiomyopathies.”
- Full press release on Phlox’ website
More news
Optics11’s new partnership for breakthrough underwater surveillance by Royal Netherlands Navy
VU spin-off Optics11, partners with Thales to equip Dutch submarines with advanced sonar technology to enhance underwater surveillance capabilities. The ability for the Royal Navy to detect threats in deep waters ensures that potential dangers are identified early. Ultimately, the advancements contribute to stronger national security, safeguarding our interests and maintaining stability. Thales delivers cutting-edge Sonar […]
News
Innovative Minds: insights from the next generation of scientist-entrepreneurs
Photograhpy by Monika Vaskorova Explore the journeys of UvA Researchers Tijmen Bakker, Olivier Lugier, and Ewelina Weglarz-Tomczak as they transformed their research into impactful startups. From developing solar cells and nanoparticles to creating enzyme-based treatments against Alzheimer’s, these scientists share their experiences of overcoming obstacles, securing funding, and utilizing university support in the context of […]
News
RehabAI@Home: public-private innovation for advancing rehabilitation
With RehabAI@Home, there is a unique public-private partnership between VU Amsterdam, Amsterdam UMC, Hogeschool van Amsterdam, and ROM InWest. The goal is to elevate innovation in rehabilitation care by combining science, artificial intelligence (AI), and entrepreneurship, making home rehabilitation more accessible and effective. Why RehabAI@Home? Healthcare faces significant challenges: The number of people […]
News